Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 11/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.43 |
| ▸ | NTRK2 | Q16620 | 3/20 | 0.43 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.42 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 2/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3662088 | 0.91 | STAT3 (0.41) | STAT3GPR119 | |
| SCHEMBL6519362 | 0.91 | GPR119 (0.45) | NTRK1KCNH2NTRK2NTRK3GRM2 | |
| SCHEMBL6521815 | 0.89 | GPR119 (0.40) | KCNH2GRM2STAT3GPR119 | |
| SCHEMBL6525462 | 0.88 | SMN1; SMN2 (0.43) | KCNH2GRM2GPR119 | |
| SCHEMBL6523552 | 0.87 | GRM2 (0.40) | KCNH2GRM2GPR119 | |
| SCHEMBL12788257 | 0.85 | GPR119 (0.42) | KCNH2GRM2GPR119 | |
| SCHEMBL3658326 | 0.84 | LIPG (0.45) | STAT3 | |
| SCHEMBL6520829 | 0.82 | STAT3 (0.42) | STAT3 | |
| SCHEMBL3654712 | 0.82 | GPR119 (0.40) | STAT3GPR119 | |
| SCHEMBL13024338 | 0.81 | MAPK1 (0.36) | GRM2STAT3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059942-A1 | Azetidinyl G-Protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
| US-20110059942-A1 | Azetidinyl G-Protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
| US-20110059942-A1 | Azetidinyl G-Protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059942-A1 | Azetidinyl G-Protein Coupled Receptor Agonists | GPR119, GIPR, GPR39 | CHRM2 473/4885CHRM5 616/4885CHRM1 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.